ATNF Stock Overview A clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
180 Life Sciences Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for 180 Life Sciences Historical stock prices Current Share Price US$1.72 52 Week High US$17.75 52 Week Low US$1.16 Beta 0.15 1 Month Change -17.70% 3 Month Change 22.86% 1 Year Change -50.80% 3 Year Change -99.86% 5 Year Change -99.96% Change since IPO -99.95%
Recent News & Updates
180 Life Sciences Corp. Appoints Steven H. Shoemaker to its Audit Committee Dec 14
180 Life Sciences Corp. Announces Board Changes Dec 04
180 Life Sciences Corp., Annual General Meeting, Dec 27, 2024 Oct 30
180 Life Sciences Corp. Appoints Jay Goodman as Independent Member of the Board of Directors and as Member of It's Audit Committee, as Well as Positions on Other Committees Oct 29
180 Life Sciences Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule Oct 11 180 Life Sciences Expects to Meet Nasdaq Minimum Shareholders Equity Requirement as of September 30, 2024 Oct 04
See more updates
180 Life Sciences Corp. Appoints Steven H. Shoemaker to its Audit Committee Dec 14
180 Life Sciences Corp. Announces Board Changes Dec 04
180 Life Sciences Corp., Annual General Meeting, Dec 27, 2024 Oct 30
180 Life Sciences Corp. Appoints Jay Goodman as Independent Member of the Board of Directors and as Member of It's Audit Committee, as Well as Positions on Other Committees Oct 29
180 Life Sciences Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule Oct 11 180 Life Sciences Expects to Meet Nasdaq Minimum Shareholders Equity Requirement as of September 30, 2024 Oct 04
180 Life Sciences Corp. Announces Chief Financial Officer Changes Sep 13
180 Life Sciences Corp. Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake Jul 30
180 Life Sciences Grants an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements Jul 23
180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million. Jul 21 180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million. Jul 20
180 Life Sciences Corp. Provides Non-Compliance Update May 24
180 Life Sciences Corp. Provides Non-Compliance Update May 23
New major risk - Financial position May 17
180 Life Sciences Corp. Receives Delist Determination Letter from Nasdaq May 16 180 Life Sciences Corp. Announces Chief Executive Officer Changes
180 Life Sciences Corp. Announces Board Resignations Dec 24
180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors Dec 21
Nasdaq Provides 180 Life Sciences Written Notice That It Complies with Terms of Prior Extension, Company Complies with Listing Rule 5635(d)(1)(A) Dec 15
180 Life Sciences Receives a Letter from Nasdaq Nov 17
High number of new directors Nov 14
180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency Oct 19
180 Life Sciences Receives Non-Compliance Notice From Nasdaq Oct 14
180 Life Sciences Corp. Receives Non-Compliance Letter from Nasdaq Sep 10
New minor risk - Share price stability Aug 10
180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake Aug 08
180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment Aug 04
180 Life Sciences Corp., Annual General Meeting, Jul 06, 2023 May 25
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement Jan 06 180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.000001 million. Dec 24
180 Life Sciences Provides Update on Progress to Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture Dec 01
No longer forecast to breakeven Nov 22
Price target decreased to US$4.00 Nov 16
High number of new and inexperienced directors Nov 16
180 Life Sciences Receives Non-Compliance Letter from Nasdaq Oct 05
180 Life Sciences Corp. Announces the First Patient Has Been Randomized in the Clinical Trial to Evaluate Anti-Tumor Necrosis Factor (TNF) for Patients with Early-Stage, Pain Predominant Frozen Shoulder Aug 23 180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.500001 million. Jul 22
180 Life Sciences to raise $6.5M in direct stock offering Jul 18
180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease Jun 15
180 Life Sciences Corp. Announces Following Publication of Promising Data from A Phase 2B Dupuytren’S Trial Jun 01
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology May 02
Price target decreased to US$5.00 Apr 27
High number of new and inexperienced directors Apr 27
180 Life Sciences Corp., Annual General Meeting, Jun 14, 2022 Apr 16
180 Life Sciences Corp. Provides an Update on its Anticipated Preliminary Discussion Mar 29
180 Life Sciences Corp. Forms Scientific Advisory Board Feb 18
Lead Independent Director recently bought US$103k worth of stock Dec 11
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results Dec 08
180 Life Sciences: Looking At Inflammation With Cannabis (Podcast) Sep 08
180 Life Sciences Corp. announced that it has received $15 million in funding Aug 25
180 Life Sciences Corp. announced that it expects to receive $15 million in funding Aug 20
180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2) Jul 14
180 Life Sciences Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q May 22
180 Life Sciences Corp. announced delayed 10-Q filing May 19
180 Life Sciences Corp. announced delayed annual 10-K filing Apr 01
180 Life Sciences Receives Extension Until June 30, 2021 to Regain Compliance from Nasdaq Mar 06
180 Life Sciences Corp. announced that it expects to receive $11.6662 million in funding Feb 20
What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry? Feb 17
New 90-day high: US$6.72 Feb 17
180 Life Sciences Corp. Announces Management Changes Dec 24
180 Life Sciences Corp. Appoints Ozan Pamir to Serve as the Interim Chief Financial Officer Dec 02
SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today Nov 27
180 Life Sciences Corp. announced delayed 10-Q filing Nov 18
180 Life Sciences Corp. Announces Management Changes Nov 14 Shareholder Returns ATNF US Biotechs US Market 7D -20.0% 0.2% -0.2% 1Y -50.8% -4.7% 25.8%
See full shareholder returns
Return vs Industry: ATNF underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: ATNF underperformed the US Market which returned 25.8% over the past year.
Price Volatility Is ATNF's price volatile compared to industry and market? ATNF volatility ATNF Average Weekly Movement 96.1% Biotechs Industry Average Movement 11.0% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ATNF's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATNF's weekly volatility has increased from 52% to 96% over the past year.
About the Company 180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
Show more 180 Life Sciences Corp. Fundamentals Summary How do 180 Life Sciences's earnings and revenue compare to its market cap? ATNF fundamental statistics Market cap US$3.40m Earnings (TTM ) -US$3.12m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ATNF income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$3.12m Earnings -US$3.12m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.58 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 13.0%
How did ATNF perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 05:50 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources 180 Life Sciences Corp. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Jason McCarthy Maxim Group Nazibur Rahman Maxim Group
Show 0 more analysts 
